302 results about "Allergen" patented technology

The invention discloses a tear total IGE detection method and system based on multi-modal data fusion. The method comprises the following steps: acquiring ocular surface images, physiological parameters and environmental allergen data, and acquiring historical medical data from a hospital information system; preprocessing and feature extraction are performed, patient symptom description is analyzed in combination with a natural language processing technology, and related image block features are recognized; adjusting a space-time attention weight based on frequency domain analysis and transfer learning, inputting a lightweight Transform model, and predicting a tear total IgE concentration and an allergy risk score; whether a trace tear sampling program is started or not is judged, and the actually measured concentration of total tear IgE is detected through a disposable micro-fluidic chip; and integrating all information by using a Bayesian adaptive filtering algorithm to determine the total tear IgE level. By implementing the method provided by the invention, the sampling amount is extremely small, the detection time is short, the environmental interference can be dynamically corrected, and the absolute concentration value is output, so that the dual requirements of clinical precise diagnosis and treatment and home monitoring are met.

The invention discloses a lactobacillus rhamnosus strain with antiallergic activity and a preparation method thereof, the strain is lactobacillus rhamnosus Lrn-PG-06, the classification name of the strain is Lactobacillus rhamnosus, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.3077, the preservation time is March 21, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.3077, and the preservation number is CGMCC No.3077. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus Lrn-PG-06 strain is high in acid resistance, alkali resistance and cholate resistance, high in simulated gastrointestinal fluid resistance and high in oxidation resistance, has the advantage of resisting allergy, and solves the problems that at present, allergic diseases are mainly treated by drugs or are prevented from being in contact with allergens in the environment and food, but due to the fact that the drugs are large in toxic and side effects, the allergens cannot be in contact with the allergens in the environment and food. And allergens causing anaphylaxis are difficult to determine, so that allergic diseases are difficult to treat or prevent.

The invention relates to the technical field of atlas generation, in particular to a children cross-allergen risk dynamic atlas generation system, which comprises the following steps: firstly, determining sensitivity indexes according to immune response conditions of each type of allergens in all allergy detection processes; according to the similarity of each allergen and other allergens in two dimensions of allergen protein structure and IgE level, combining the sensitivity index, and comprehensively representing the cross reaction risk index of each allergen in each allergy detection process; then comprehensively determining the cross-allergy risk degree of various allergens in each season period according to the increasing trend of the cross-allergy risk index curve in each season period and the overall size of the cross-allergy risk index in combination with the characteristic that the cross-allergy reaction possibly caused by the season change is dynamically changed; and the cross allergen risk dynamic map generated in real time according to the cross allergen risk degree is more accurate.

The present invention provides a composition for use in the prevention and / or treatment of a viral infection in an individual wherein the composition comprises Bifidobacterium longum subsp. Infantis and a mixture of HMO consisting of 2 '-fucosyllactose (2FL), difucosyllactose (DFL), lactose-N-tetraose (LNT), 6'-sialyllactose (6SL), 3 '-sialyllactose (3SL), and 3-fucosyllactose (3FL). The present invention also provides compositions for use in preventing and / or reducing the risk of allergen sensitization, preventing and / or reducing the risk of developing respiratory disorders in an individual, and / or preventing and / or reducing the risk of developing asthma in an individual.

The invention discloses manganese-based Prussian blue-polyacrylic acid / polyvinyl alcohol hydrogel for preventing and treating allergic rhinitis. Monodisperse manganese-based Prussian blue nanoparticles synthesized by taking polyacrylic acid as a template are stably immobilized in a polyacrylic acid / polyvinyl alcohol hydrogel matrix. The obtained composite hydrogel membrane has the following prominent advantages: the composite hydrogel membrane has excellent hydrogel characteristics, including controllable membrane thickness, good tissue adhesion and air permeability; reliable biocompatibility and safety are shown; allergen permeation is effectively blocked through a physical barrier effect; prussian blue is continuously released in the slow-release degradation process, active oxygen free radicals are remarkably removed, and the powerful anti-inflammatory effect is achieved. Due to the synergistic effect of double mechanisms of protection and treatment, the material has important clinical application value and development potential in the fields of prevention and treatment of allergic rhinitis.

The present invention relates to a composition comprising a Bifidobacterium longum transitional microorganism and a mixture of human milk oligosaccharides (HMOs) consisting of 2'-fucosyllactose (2'-FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), and 3'-sialyllactose (3SL), and optionally lacto-N-fucopentaose I (LNFP-I), 3- fucosyllactose (3-FL) and / or lacto-N-neotetraose (LNnT), wherein the Bifidobacterium longum transitional microorganism has an Average Nucleotide Identity (ANI) of at least 98% with CNCM I-5942. The invention also relates to the use of the composition for preventing, reducing the risk of and / or treating an infection in a subject. The invention also provides the composition for use in promoting a long-term immune benefit in a subject, preventing and / or reducing the risk of allergen sensitisation, preventing and / or reducing the risk of developing a respiratory condition in a subject, and / or preventing and / or reducing the risk of developing asthma in a subject.

The invention provides a portunus trituberculatus SCP antigen, antibody, kit and application, and belongs to the technical field of allergen detection. The antigen of the portunus trituberculatus SCP comprises an antigen epitope peptide of the portunus trituberculatus SCP and a carrier protein, and the amino acid sequence of the antigen epitope peptide of the portunus trituberculatus SCP is as shown in SEQ ID NO. 14. The antigen epitope peptide of the antigen portunus trituberculatus SCP has a relatively stable structure before and after thermal processing, the detection limit of an antibody prepared from the antigen for detecting a crustacean allergen is 0.32 mu g / mL, the quantitation limit is 1.06 mu g / mL, the crustacean allergen can be specifically detected, and the antibody can be used for detecting the crustacean allergen. In addition, when the antibody is used for detecting the crustacean allergen, the accuracy is good, the matrix interference resistance and the precision are high, and the high detection effect on the crustacean allergen in food processed at high temperature can still be kept.

The invention discloses a preparation method and application of a cat main allergen FEL-1 nano antibody FEL-1-Nb, and relates to the technical field of antibody preparation, and the preparation method comprises the following steps: preparing an immunogen; animal immunization and library construction; constructing and panning a phage display library; screening and identifying positive clone; and expression and purification of the nano antibody: cloning the positively cloned VHH gene to an expression vector such as a pET series, transforming an expression strain such as escherichia coli BL21 (DE3), carrying out IPTG induced expression, and purifying through an inclusion body purification method to obtain a high-purity nano antibody protein. The nano antibody FEL-1-Nb provided by the invention can be specifically bound with a cat main allergen FEL-1 protein, the unique amino acid sequence of the nano antibody FEL-1-Nb is shown as SEQIDNO: 1, high-affinity binding with the FEL-1 protein is ensured, the positive clone binding rate is high through phage display panning and ELISA verification, the phage recovery rate after the third round of panning is increased by more than 1000 times compared with the first round of panning, and the positive clone binding rate is higher than that of the first round of panning. Therefore, the nano antibody has excellent targeted recognition capability.

The present invention aims to treat hay fever by providing water from which pollen (an allergen) has been removed using the pollen treatment facility C of the present invention. [Solution] In a water treatment system consisting of a water tower B, a water treatment plant D, a sand filtration area E, and a water distribution reservoir F, a pollen treatment facility is provided to remove pollen from the river water 1 supplied to the water treatment plant D.

The invention relates to the technical field of allergen proteins and antigen epitopes, and discloses an Antarctic krill allergen and an identification method and application of the Antarctic krill allergen, the Antarctic krill allergen and the antigen epitopes are used for identifying the Antarctic krill allergen and the antigen epitopes, and the identification method comprises the steps of Antarctic krill crude protein extraction, Antarctic krill allergen screening and identification. Extracting an antarctic krill map and verifying allergens; analyzing the homology of the euphausia superba and analyzing the conformation of tropomyosin of the euphausia superba; carrying out euphausia superba tropomyosin epitope analysis; and allergens and epitopes of the euphausia superba are applied. According to the invention, the antarctic krill allergen is identified as tropomyosin, eight antigen epitopes of the antarctic krill tropomyosin allergen are ascertained, the stability change rule in the hot working process is analyzed by utilizing the identified antarctic krill allergen and antigen epitopes, and the result shows that the stability of the antarctic krill allergen is greatly improved under the processing condition of 140 DEG C or below. And the conformation of the tropomyosin of the euphausia superba and the binding capacity of the tropomyosin with protein immune globulin E or immune globulin G are kept stable.

The invention relates to an allergen detection task generation method, a detection method and a sample analyzer. The method comprises the following steps: identifying detection information of a detection sheet, and determining an allergen detection type; according to the allergen detection type, a detection work order used for indicating detection items is displayed, and the detection items comprise a fixed detection item group and a to-be-selected detection item group; based on a selection instruction of a user, determining a plurality of to-be-selected detection items corresponding to the detection information from the to-be-selected detection item group, and forming an elastic detection item group; and generating an allergen detection task according to the fixed detection item group, the elastic detection item group and the reference detection item. According to the scheme provided by the invention, the allergen can be subjected to elastic combined detection, and the detection cost of a patient is reduced.

The invention discloses a child allergen confirmation method and system based on online data transmission, and relates to the technical field of data transmission. The method comprises the steps of encrypting and transmitting collected child biological monitoring data to a parent terminal based on an asymmetric key pair, and generating an updated asymmetric key pair; based on the symmetric key, encrypting and transmitting the child biological monitoring data and the input child allergen description data to an analysis terminal, and generating an updated symmetric key; using a child allergen knowledge graph to extract child allergen information of the child allergen description data and the child biological monitoring data, and performing auditing to obtain standard child allergen information; and based on the updated symmetric key, encrypting and transmitting the standard child allergen information to the parent terminal, and checking the standard child allergen information. The problems of data potential safety hazards, key management rigidity and insufficient data processing accuracy in the prior art are solved.

In one embodiment, the present disclosure provides hypoallergenic peanut allergen AraH6 variants, in which at least one epitope recognized by an anti-AraH6 antibody has been altered, thereby reducing or eliminating antibody binding to the peanut allergen. Such hypoallergenic peanut allergen variants retain immunogenicity and can be used in methods for treating and reducing the severity of peanut allergies in subjects (patients) with peanut allergies.

This invention provides a peanut allergen peptide, its screening method, and its application. Phage display technology is used to screen for conformational epitopes of Ara h5 and Ara h8 proteins. Polyclonal IgE and IgG antibodies against the target proteins are prepared by immunizing BALB / c mice with Ara h5 and Ara h8 proteins as antigens. ELISA and dotted immunoblotting detection revealed that the titers of polyclonal IgG and IgE against Ara h5 and Ara h8 proteins were 1:64000 and 1:320, respectively, and the antibodies exhibited specificity. Using the antibodies as targets, phage display technology screened the conformational epitope sequences of Ara h5 protein as WETIYSR and FHWWYLK. The conformational epitopes of Ara h8 protein were FPYMKFV, FPYMKFR, SMFARID, and SFHWWLF.

The invention provides the primer and the detection kit for detecting the culicoides chromogen immune mouse B cell receptor repertoire, the amplified B cells and plasma cell clone can be identified and quantified by screening the BCR repertoire by utilizing the kit, and the kit has the advantages of high throughput, rapid and accurate detection and the like. Experiments show that a basis is provided for the research on the immune mechanism of the culicoides leucoides allergen.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

There is provided a method for decreasing leakage of matter from an object to a surrounding, said object being coated with a coating at least partially applied on the object, said coating comprising an at least partially covering layer comprising silver, said object optionally comprising area(s) without said layer, said coating comprising metal particles applied on the layer and optionally on areas without said layer, said metal particles comprising palladium and at least one metal selected from the group consisting of gold, ruthenium, rhodium, osmium, iridium, niobium, neodymium and platinum and wherein the amount of the metal particles is in the interval 0.01-8 μg / cm . Advantages include that leakage of matter such as latex allergens of metal ions can be reduced while the coating is both biocompatible and antimicrobial. Further, the blood clotting can be reduced.

The invention discloses an enzyme preparation for degrading allergens of pet food and application of the enzyme preparation, the enzyme preparation is a pH-responsive acrylic resin-pectin composite double-response shell embedded enzyme-probiotic composite system, a core layer is heat-resistant neutral protease, and a middle layer is a compound of lactobacillus reuteri and bacillus subtilis. In the processing stage, the protease degrades macromolecular allergens, the composite shell in the gastrointestinal environment firstly triggers outer acrylic resin to be dissolved through weak alkalinity of the intestinal tract, then inner pectin is degraded by pancreatin, and probiotics are accurately released to metabolize residual sensitizing peptides. The enzyme preparation realizes full-chain desensitization, is high in survival rate of probiotics, is suitable for various pet foods, and is stable and reliable in desensitization effect.

This invention discloses an essence for repairing hormone-induced facial dermatitis and its application, belonging to the field of cosmetics and skin repair technology. The essence uses deionized water as the main solvent, with butylene glycol and glycerin as the core moisturizing base. It is compounded with five major active ingredients: niacinamide, Bacillus ferment precipitate, mussel extract, sodium hyaluronate, and allantoin, supplemented with auxiliary components such as 1,3-propylene glycol, capryloyl hydroxamic acid, 1,2-hexanediol, ethylhexylglycerin, disodium EDTA, and ethanol. Through scientific compounding, a synergistic repair system is formed, achieving integrated effects of skin barrier repair, anti-inflammatory soothing, microecological balance regulation, deep moisturizing and water locking, and redness reduction and stabilization. The formula of this invention is gentle and non-irritating, free of hormones, fragrances, pigments, and strong allergens, suitable for use on hormone-induced facial dermatitis, dermatitis-prone skin, and severely sensitive skin. The product has good stability, high safety, and is suitable for industrial production, possessing significant skin repair value and promising market application prospects.

The present invention provides a universal protein renaturation method and an application thereof, and relates to the technical field of protein renaturation. The method includes the following steps: (1) add 2mercaptoethanol to urea solution to obtain denaturing solution; (2) dissolve a sample including to-be-renatured protein by using the denaturing solution and then freeze the sample, to obtain a frozen body; (3) thaw the frozen body at room temperature, and extract the thawed liquid as soon as the liquid is thawed; (4) dilute the extracted liquid with water, to terminate renaturation and obtain supernatant and precipitate through centrifugation, where the supernatant includes the protein that has been successfully renatured. According to the present invention, protein renaturation recovery efficiency can be improved, and a production batch is stable and reproducible. Operations in the present invention are simple, almost no waste liquid is produced, and no protein is lost. According to the present invention, nine allergen proteins are renatured, to significantly improve the protein renaturation yield. In addition, compared with that in the conventional technology, the protein activity according to the present invention is increased by about 3 times or more.

A sublingual tablet and application thereof in desensitization therapy drug are provided. The sublingual tablet is a low-dose allergen sublingual tablet. The sublingual tablet includes freeze-dried powder of allergen protein, lactose, mannitol, low substituted hydroxypropyl cellulose, low moisture microcrystalline cellulose, and magnesium stearate. The freeze-drying process is adopted to obtain the freeze-dried powder of allergen protein, and the powder direct compression technology is adopted to obtain the sublingual tablet of allergen protein. The low-dose sublingual tablet has excellent properties, including appearance, hardness, tablet weight variation, disintegration time, taste, and uniformity of content, in particular has outstanding advantages in disintegration time, uniformity of content, stability, and preparation process, and has an industrial application prospect.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The present application relates to novel immunotherapeutic compositions and uses thereof. The present invention relates generally to an immunotherapeutic composition. More specifically, the present invention relates to an immunotherapeutic composition that immunointeracts with T lymphocytes in a subject suffering from peanut allergy or allergy to other tree nuts. Such compositions preferably react immunologically with T cells in a subject suffering from an allergy to an Ara h 1 and / or Ara h 2 allergen. The compositions of the present invention are useful in the therapeutic or prophylactic treatment of conditions characterized by an abnormal, improper or otherwise unwanted immune response to peanut, Ara h1 and / or Ara h2, or a derivative or homolog thereof.

Methods and devices are provided for treating a food allergy in a subject in need thereof. The method entails delivering an effective amount of an allergen associated with the food allergy into the subject's cutis skin layer. Delivering the allergen is carried out by inserting one or more allergen-coated solid microneedles into the subject's skin. The one or more solid microneedles each has a base, shaft and tip, and when inserted in the subject, do not extend beyond the cutis. The allergen is allowed to dissociate from the one or more microneedles while inserted in the subject's cutis. Once the allergen disassociates, the one or more microneedles is removed from the subject's skin.

The invention provides an allergy risk prediction method and device based on indoor physical environment simulation and electronic equipment, and relates to the technical field of medical health data analysis, and the method comprises the steps: constructing a parameterized three-dimensional building model based on spatial information; based on the three-dimensional building model and the external meteorological parameters, coupled physical field simulation is carried out on sunlight, natural lighting and natural ventilation conditions in the target building space, and quantitative environment field distribution data is obtained; matching and fusing the environment field distribution data with a preset risk mapping rule based on allergen breeding physical conditions, identifying and dividing different levels of environment risk areas in the target building space, and generating a visual risk distribution map with space coordinates; and generating a personalized report containing a targeted environment intervention strategy bound with the spatial position based on the specific risk area position and the grade thereof in the risk distribution map. According to the method, quantitative environment data support is provided, and health suggestions are upgraded from experience judgment to data decision.

The present invention provides novel antigens of an allergy to fish, methods and kits for diagnosing an allergy to fish, pharmaceutical compositions comprising such an antigen, fishes, fish eggs or processed products of such fish or fish egg in which such an antigen is eliminated, fishes that deliver such fish eggs or are born from such fish egg, and a tester for determining the presence or absence of a fish antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an antigen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and raw materials or processed products in which an antigen comprising such a polypeptide is eliminated or reduced. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.

The invention discloses a nasal cavity biological protection preparation, a preparation method and application thereof and a nasal cavity intelligent protection system. The formulation comprises a mucin inspired polymer having a specific "brush-like bottleneck" molecular configuration, and an interpenetrating network formed from oppositely charged polysaccharides, which construct a three-dimensional hydrated gel by dynamic non-covalent cross-linking. The gel has the characteristics of shear thinning, strong mucous membrane adhesion and efficient particle interception. Temperature-sensitive, pH-sensitive or oxidation-reduction-sensitive intelligent microspheres can also be integrated in the preparation, so that responsiveness protection to the external environment is realized. The invention further provides an intelligent protection scheme comprising the preparation, a quantitative spraying device and a simple monitoring system. The preparation is safe and free of medicine, is suitable for preventing nasal cavity discomfort caused by air pollution, allergens, viruses and environment dryness, and is especially suitable for daily health protection under high-risk environment or extreme weather conditions.